|
1
|
Shukla S and Gupta S: Apigenin: A
promising molecule for cancer prevention. Pharm Res. 27:962–978.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rezai-Zadeh K, Ehrhart J, Bai Y, Sanberg
PR, Bickford P, Tan J and Shytle RD: Apigenin and luteolin modulate
microglial activation via inhibition of STAT1-induced CD40
expression. J Neuroinflammation. 5:412008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moon DO, Kim MO, Choi YH, Lee HG, Kim ND
and Kim GY: Gossypol suppresses telomerase activity in human
leukemia cells via regulating hTERT. FEBS Lett. 582:367–373. 2008.
View Article : Google Scholar
|
|
4
|
Nakazawa T, Yasuda T, Ueda J and Ohsawa K:
Antidepressant-like effects of apigenin and
2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced
swimming test. Biol Pharm Bull. 26:474–480. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hashemi M, Nouri Long M, Entezari M,
Nafisi S and Nowroozii H: Anti-mutagenic and pro-apoptotic effects
of apigenin on human chronic lymphocytic leukemia cells. Acta Med
Iran. 48:283–288. 2010.
|
|
6
|
Patel D, Shukla S and Gupta S: Apigenin
and cancer chemoprevention: progress, potential and promise
(review). Int J Oncol. 30:233–245. 2007.
|
|
7
|
Shukla S and Gupta S: Molecular targets
for apigenin-induced cell cycle arrest and apoptosis in prostate
cancer cell xenograft. Mol Cancer Ther. 5:843–852. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang YC, Huang YT, Tsai SH, Lin-Shiau SY,
Chen CF and Lin JK: Suppression of inducible cyclooxygenase and
inducible nitric oxide synthase by apigenin and related flavonoids
in mouse macrophages. Carcinogenesis. 20:1945–1952. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Birt DF, Mitchell D, Gold B, Pour P and
Pinch HC: Inhibition of ultraviolet light induced skin
carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid.
Anticancer Res. 17:85–91. 1997.PubMed/NCBI
|
|
10
|
Seo HS, Ju JH, Jang K and Shin I:
Induction of apoptotic cell death by phytoestrogens by
up-regulating the levels of phospho-p53 and p21 in normal and
malignant estrogen receptor α-negative breast cells. Nutrition Res.
31:139–146. 2011. View Article : Google Scholar
|
|
11
|
Lu HF, Chie YJ, Yang MS, Lee CS, Fu JJ,
Yang JS, Tan TW, Wu SH, Ma YS, Ip SW and Chung JG: Apigenin induces
caspase-dependent apoptosis in human lung cancer A549 cells through
Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol.
36:1477–1484. 2010.PubMed/NCBI
|
|
12
|
Wang W, Heideman L, Chung CS, Pelling JC,
Koehler KJ and Birt DF: Cell-cycle arrest at G2/M and growth
inhibition by apigenin in human colon carcinoma cell lines. Mol
Carcinog. 28:102–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Turktekin M, Konac E, Onen HI, Alp E,
Yilmaz A and Menevse S: Evaluation of the effects of the flavonoid
apigenin on apoptotic pathway gene expression on the colon cancer
cell line (HT29). J Med Food. 14:1107–1117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta S, Afaq F and Mukhtar H: Involvement
of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle
arrest and apoptosis by apigenin in human prostate carcinoma cells.
Oncogene. 21:3727–3738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruela-de-Sousa RR, Fuhler GM, Blom N,
Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of
apigenin on leukemia cell lines: implications for prevention and
therapy. Cell Death Dis. 1:e192010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ,
Golkar L, Milam B, Talamonti MS, Bell RH Hr, Iwamura T and Adrian
TE: Apigenin inhibits pancreatic cancer cell proliferation through
G2/M cell cycle arrest. Mol Cancer. 5:762006. View Article : Google Scholar
|
|
17
|
Fan TJ, Han LH, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar
|
|
18
|
Bosch M, Poulter NS, Vatovec S and
Franklin-Ton VE: Initiation of programmed cell death in
self-incompatibility: role for cytoskeleton modifications and
several caspase-like activities. Mol Plant. 1:879–887. 2008.
View Article : Google Scholar
|
|
19
|
Zhang A, Wu Y, Lai HWL and Yew DT:
Apoptosis-a brief review. Neuroembryology. 3:47–59. 2004.
View Article : Google Scholar
|
|
20
|
Waring P and Mullbacher A: Cell death
induced by the Fas/Fas ligand pathway and its role in pathology.
Immunol Cell Biol. 77:312–317. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta S: Molecular signaling in death
receptor and mitochondrial pathways of apoptosis (review). Int J
Oncol. 22:15–20. 2003.
|
|
22
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boulares AH, Yakovlev AG, Ivanova V,
Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose)
polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP
mutant increases rates of apoptosis in transfected cells. J Biol
Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilson CA, Cajulis EE, Green JL, Olsen TM,
Chung YA, Damore MA, Dering J, Calzone FJ and Slamon DJ: HER-2
over-expression differentially alters transforming growth
factor-beta responses in luminal versus mesenchymal human breast
cancer cells. Breast Cancer Res. 7:R1058–R1079. 2005. View Article : Google Scholar
|
|
25
|
Prat A, Carey LA, Adamo B, Vidal M,
Tabernero J, Cortés J, Parker JS, Perou CM and Baselga J: Molecular
features and survival outcomes of the intrinsic subtypes within
HER2-positive breast cancer. J Natl Cancer Inst. 106:dju1522014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Joshi JP, Brown NE, Griner SE and Nahta R:
Growth differentiation factor 15 (GDF15)-mediated HER2
phosphorylation reduces trastuzumab sensitivity of
HER2-overexpressing breast cancer cells. Biochem Pharmacol.
82:1090–1099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Favoni RE, Daga A, Malatesta P and Florio
T: Preclinical studies identify novel targeted pharmacological
strategies for treatment of human malignant pleural mesothelioma.
Br J Pharmacol. 166:532–553. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tokunaga E, Oki E, Nishida K, Koga T,
Egashira A, Morita M, Kakeji Y and Maehara Y: Trastuzumab and
breast cancer: Developments and current status. Int J Clin Oncol.
11:199–208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dean-Colomb W and Esteva FJ: Her2-positive
breast cancer: Herceptin and beyond. Eur J Cancer. 44:2806–2812.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seo HS, Choi HS, Kim SR, Choi YK, Woo SM,
Shin I, Woo JK, Park SY, Shin YC and Ko SG: Apigenin induces
apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3
and NFκB signaling in HER2-overexpressing breast cancer cells. Mol
Cell Biochem. 366:319–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Earnshaw WC, Martins LM and Kaufmann SH:
Mammalian caspases: structure, activation, substrates and functions
during apoptosis. Annu Rev Biochem. 68:383–424. 1999. View Article : Google Scholar
|
|
32
|
Blagosklonny MV, An WG, Romanova LY,
Trepel J, Fojo T and Neckers L: p53 inhibits hypoxia-inducible
factor-stimulated transcription. J Biol Chem. 273:11995–11998.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R,
Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by Hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996.PubMed/NCBI
|
|
35
|
Jung JE, Lee HG, Cho IH, Chung DH, Yoon
SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK and Chung MH: STAT3 is
a potential modulator of HIF-1-mediated VEGF expression in human
renal carcinoma cells. FASEB J. 19:1296–1298. 2005.PubMed/NCBI
|
|
36
|
Hagemann T, Robinson SC, Schulz M, Trümper
L, Balkwill FR and Binder C: Enhanced invasiveness of breast cancer
cell lines upon co-cultivation with macrophages is due to TNF-alpha
dependent up-regulation of matrix metalloproteases. Carcinogenesis.
25:1543–1549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
de la Iglesia N, Konopka G, Puram SV, Chan
JA, Bachoo RM, You MJ, Levy DE, DEPinho RA and Bonni A:
Identification of a PTEN-regulated STAT3 brain tumor suppressor
pathway. Genes Dev. 22:449–462. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lewis HD, Winter A, Murphy TF, Tripathi S,
Pandey VN and Barton BE: STAT3 inhibition in prostate and
pancreatic cancer lines by STAT3 binding sequence oligonucleotides:
Differential activity between 5′ and 3′ ends. Mol Cancer Ther.
7:1543–1550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kortylewski M, Jove R and Yu H: Targeting
STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev.
24:315–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Niu G, Bowman T, Huang M, Shivers S,
Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H: Roles of
activated Src and Stat3 signaling in melanoma tumor cell growth.
Oncogene. 21:7001–7010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu
M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3
in human melanoma promotes brain metastasis. Cancer Res.
66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sellers LA, Feniuk W, Humphrey PP and
Lauder H: Activated G proteincoupled receptor induces tyrosine
phosphorylation of STAT3 and agonist-selective serine
phosphorylation via sustained stimulation of mitogen-activated
protein kinase. Resultant effects on cell proliferation. J Biol
Chem. 274:16423–16430. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Y, Turkson J, Carter-Su C, Smithgall
T, Levitzki A, Kraker A, Krolewski JJ, Medveczky P and Jove R:
Activation of Stat3 in v-Src-transformed fibroblasts requires
cooperation of Jak1 kinase activity. J Biol Chem. 275:24935–24944.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kotha A, Sekharam M, Cilenti L, Siddiquee
K, Khaled A, Zervos AS, Carter B, Turkson J and Jove R: Resveratrol
inhibits src and Stat3 signaling and induces the apoptosis of
malignant cells containing activated Stat3 protein. Mol Cancer
Ther. 5:621–629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tolaney SM and Krop IE: Mechanisms of
trastuzumab resistance in breast cancer. Anticancer Agents Med
Chem. 9:348–355. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buzdar AU: Role of biologic therapy and
chemotherapy in hormone receptor- and HER2-positive breast cancer.
Ann Oncol. 20:993–999. 2009. View Article : Google Scholar : PubMed/NCBI
|
